ANNOVIS BIO(NYSE:ANVS) stock News

ANVS Latest News, Press Relases and Analysis

All

Press Releases

8 days ago - By: Benzinga - Mentions: WTFC BWA CHE MTB ...

Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

9 days ago - By: Annovis Bio Inc.

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: The Motley Fool

Annovis Bio Narrows Loss in Q2

a month ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

3 months ago - By: Annovis Bio Inc.

Annovis to Host Webinar and Live Q&A on June 24, 2025

6 months ago - By: Annovis Bio Inc.

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

7 months ago - By: Annovis Bio, Inc.

Annovis to Host Patients’ Live Forum on February 27, 2025

a month ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

a month ago - By: Annovis Bio Inc.

Annovis Completes Full Patent Transfer to Crystal Buntanetap

2 months ago - By: Benzinga - Mentions: SHOT BLMZ TWG AGYS ...

Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket

3 months ago - By: Annovis Bio Inc.

Annovis to Attend the AAIC 2025 with Four Poster Presentations

3 months ago - By: Annovis Bio Inc.

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

3 months ago - By: Annovis Bio Inc.

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

3 months ago - By: Annovis Bio Inc.

Annovis to Host Webinar and Live Q&A on June 24, 2025

4 months ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

4 months ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

4 months ago - By: Annovis Bio Inc.

Annovis Bio Appoints Hui Liu as Director of Biostatistics

6 months ago - By: Annovis Bio Inc.

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

6 months ago - By: Annovis Bio Inc.

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

6 months ago - By: Annovis Bio Inc.

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

6 months ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

6 months ago - By: Annovis Bio Inc.

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

6 months ago - By: Annovis Bio Inc.

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

7 months ago - By: Annovis Bio, Inc.

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

7 months ago - By: Annovis Bio, Inc.

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

7 months ago - By: Annovis Bio, Inc.

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

7 months ago - By: Annovis Bio, Inc.

ANNOVIS BIO (ANVS) Stock News

ANVS Latest News, Press Relases and Analysis

Alphabet To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday

Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Annovis Bio Narrows Loss in Q2

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis to Host Patients’ Live Forum on February 27, 2025

Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results

Annovis Completes Full Patent Transfer to Crystal Buntanetap

Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket

Annovis to Attend the AAIC 2025 with Four Poster Presentations

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance

Annovis to Host Webinar and Live Q&A on June 24, 2025

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results

Annovis Bio Appoints Hui Liu as Director of Biostatistics

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering